EDAP TMS S.A. Launches www.HIFU-Planet.com
22 April 2006 - 3:28AM
PR Newswire (US)
Online Tools Help Patients, Doctors Learn About HIFU Options,
Benefits in Treating Localized Prostate Cancer LYON, France, April
21 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP) announced
the launch of http://www.hifu-planet.com/ , an online education
resource to help both patients and doctors learn about high
intensity focused ultrasound treatment of localized prostate
cancer. EDAP is considered the global leader in HIFU treatment of
localized prostate cancer through its industry-leading
Ablatherm-HIFU unit, which has been in use in Europe for now more
than 10 years with excellent clinical outcomes and low side
effects. Ablatherm-HIFU has the largest body of clinical experience
and data of any HIFU therapy for localized prostate cancer. "EDAP
is aggressively expanding its education efforts directed to
patients and doctors now that the Ablatherm-HIFU has clear and
credible long-term outcomes supporting it as a clear option for
localized prostate cancer," said Fabrice Romano, Director of
Marketing for EDAP. "In 2005 the company focused on growing its
user base to reach a broader population achieving a 50% increase in
sites in just one year and a sustainable growth pattern. With now
more than 105 sites we are broadening our efforts to include not
only launching new centers but also reaching out to potential
patients to drive more treatments at centers using Ablatherm-HIFU.
The company's recent success at the EAU Congress in Paris clearly
demonstrated the significant upwelling of doctor interest based on
the clinical success of Ablatherm-HIFU. With this strong support
from the medical community we are now able to reach out directly to
patients and help them learn about an effective and attractive
treatment option, which may offer them advantages compared to their
present choices. This new program and others will help to increase
the number of patients treated at current and future centers making
Ablatherm-HIFU therapy even more prevalent in the urology and
patient communities." The site offers patients and doctors basic
information about HIFU treatment, its effectiveness as reported in
multiple clinical studies, patient testimonials, interactive
discussions and the considerations in determining if HIFU therapy
should be in the list of choices considered by patients as they
consult with their physician. A 3-D video description of the
Ablatherm-HIFU treatment process is also available on the site to
help patients and doctors understand how the treatment works.
Patients wanting to learn more can also submit questions through an
interactive anonymous Q&A answered by medical professionals
experienced in the use of Ablatherm-HIFU. The questions and answers
will be archived online helping add to the depth of knowledge on
HIFU on the site. Patients interested in pursuing Ablatherm-HIFU
can locate a center near their home if they wish to schedule a
consultation with medical staff experienced in the use of
Ablatherm-HIFU to treat localized prostate cancer. "EDAP and the
Ablatherm-HIFU have been carefully tested by top medical
professionals throughout Europe with excellent clinical outcomes in
efficacy against localized prostate cancer while keeping side
effects very low," said Rafael Varona, Medical Director of EDAP.
"We see more patients and doctors now electing to pursue
Ablatherm-HIFU because it is the only HIFU therapy that can provide
detailed, long-term results from multiple centers demonstrating its
success for both first indication and salvage therapy patients.
Ablatherm-HIFU helps patients maintain a better quality of life
providing rapid treatment averaging less than two hours, quick
recovery measured in days or weeks rather than months, and less
need for follow up care on side effects that can reduce a patient's
ability to pursue the activities they enjoy. But perhaps our best
advocates are the patients who have been treated over the past 10
years who can excitedly attest to the benefits of this therapeutic
choice." Recent long-term clinical data demonstrate Ablatherm-HIFU
is successful as a curative option for localized prostate cancer in
up to 93 percent of patients following treatment. Patients are able
to confirm their success by PSA or biopsy accurately within just 3
months of treatment. Incontinence occurred in less than 2 percent
of patients. As a salvage therapy, Ablatherm- HIFU demonstrated a
success rate of 76 percent on patients who failed prior radiation
therapy, many of whom were considered untreatable by traditional
methods. Doctors experienced in Ablatherm-HIFU will be able to
discuss the clinical studies as they apply to each patient's unique
case as well as advantages of Ablatherm-HIFU as compared to other
options as they work with the patient to make an informed decision
about the best course of care. About EDAP TMS S.A. EDAP TMS S.A.
develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU)
treatment of localized prostate cancer. HIFU treatment is shown to
be a minimally invasive and effective treatment option with a low
occurrence of side effects. Ablatherm-HIFU is generally recommended
for patients with localized prostate cancer (stages T1-T2) who are
not candidates for surgery or who prefer an alternative option or
patients who failed radiotherapy treatment. The company is also
developing this technology for the treatment of certain other types
of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using
Extra-corporeal Shockwave Lithotripsy (ESWL). For more information
on the Company, contact Halliburton Investor Relations at (972)
458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26
40 46 or see the Company's Web sites at http://www.edap-tms.com/
and http://www.hifu-planet.com/ . This press release contains, in
addition to historical information, forward-looking statements that
involve risks and uncertainties. These include statements regarding
the Company's growth and expansion plans. Such statements are based
on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. Ablatherm-HIFU treatment is in
clinical trials but not yet FDA approved or marketed in the United
States. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe Chauveau
Blandine Confort +33 4 78 26 40 46 Halliburton Investor Relations
Matt Kreps - Geralyn DeBusk 972 458 8000 DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine Confort,
all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps, or Geralyn
DeBusk, both of Halliburton Investor Relations, +1-972-458-8000,
for EDAP TMS S.A. Web site: http://www.edap-tms.com/
http://www.hifu-planet.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024